newli
emerg
reemerg
infect
respiratori
tract
pose
consider
medic
public
health
concern
well
econom
hardship
human
countri
last
centuri
wit
least
five
pandem
h
viral
hemagglutinin
n
viral
neuraminidas
spanish
influenza
asia
influenza
hong
kong
influenza
russian
influenza
bird
influenza
review
wright
et
al
twentyfirst
centuri
alon
two
viral
pandem
alreadi
first
new
viral
pandem
sever
acut
respiratori
syndrom
sar
appear
review
oldston
follow
first
influenza
viru
pandem
swine
influenza
dawood
et
al
moreov
hantavirus
infect
human
past
recent
outbreak
yellowston
nation
park
viral
infect
loom
import
zoonot
human
diseas
threat
human
human
transmiss
excess
high
mortal
rate
exampl
influenza
infect
caus
greatest
loss
life
infecti
diseas
medic
condit
known
visit
roughli
world
popul
kill
million
person
ahm
et
al
johnson
mueller
recent
influenza
pandem
swine
influenza
rapidli
infect
million
worldwid
estim
exceed
death
result
respiratori
failur
cardiovascular
complic
dawood
et
al
diseas
human
arankal
et
al
cheng
et
al
lee
et
al
experiment
anim
baskin
et
al
kobasa
et
al
marcelin
et
al
zhang
et
al
accompani
earli
exacerb
dysregul
innat
immun
respons
combin
event
call
cytokin
storm
sever
diseas
death
follow
infect
correl
strongli
cytokin
storm
suscept
resist
viral
infect
determin
balanc
virul
infect
agent
resist
host
includ
aggress
latter
immun
respons
viru
infect
immun
respons
limit
due
either
host
genet
acquir
defect
like
lymphoid
diseas
immatur
immun
system
fetus
newborn
young
children
loss
immun
vigor
age
advantag
firmli
viru
court
howev
usual
infect
occur
individu
develop
compet
immun
system
advantag
host
unless
infect
viru
overwhelm
individu
immun
system
immun
respons
becom
hyperact
result
excess
innat
adopt
immun
reaction
cytokin
storm
phenomenon
cytokin
storm
lead
immunemedi
injuri
immunopatholog
avail
vaccin
use
protect
group
previous
uninfect
naiv
individu
acut
viral
respiratori
diseas
mean
spread
infect
diminish
addit
antivir
drug
develop
effect
therapi
diminish
instanc
prevent
ongo
infect
reason
effect
nevertheless
come
two
mark
limit
first
antivir
drug
exert
select
pressur
viral
progeni
promot
mutat
select
therebi
creat
new
gener
fit
resist
drug
nguyen
et
al
orozov
et
al
second
injuri
associ
acut
viral
respiratori
diseas
includ
influenza
result
combin
viru
intrins
virul
lyse
cell
infect
intens
immun
respons
damag
tissu
promot
cytokin
storm
antivir
drug
effect
viru
cytokin
storm
immunemedi
injuri
recent
studi
human
influenza
viru
infect
mice
walsh
et
al
teijaro
et
al
ferret
teijaro
et
al
uncov
first
direct
definit
experiment
evid
cytokin
storm
per
se
major
factor
causat
morbid
mortal
influenza
viru
acut
sever
respiratori
infect
rather
accompani
phenomena
document
cytokin
storm
chemic
treatabl
use
immunomodulatori
small
molecul
agonist
dramat
inhibit
product
cytokineschemokin
innat
cellular
respons
therebi
blunt
innat
well
adopt
antivir
cell
respons
marsolai
et
al
walsh
et
al
teijaro
et
al
event
success
limit
immunopatholog
injuri
nevertheless
suffici
host
cell
respons
remain
coupl
antivir
antibodi
respons
curtail
acut
infect
provid
recal
immunolog
memori
renew
insult
viru
review
focus
primarili
experiment
work
provid
conclus
overli
aggress
innat
immun
respons
earli
recruit
inflammatori
leukocyt
lung
dysregul
immun
gene
express
key
contributor
morbid
influenza
viru
onslaught
suggest
experiment
infect
macaqu
viru
strain
kobasa
et
al
cilloniz
et
al
clinic
studi
human
infect
bird
influenza
viru
reveal
signific
associ
excess
earli
cytokin
respons
immun
cell
recruit
strongli
predict
poor
medic
outcom
de
jong
et
al
recent
similar
result
influenza
viru
infect
report
experiment
anim
model
baskin
et
al
marcelin
et
al
zhang
et
al
human
arankal
et
al
cheng
et
al
lee
et
al
among
report
pandem
influenza
infect
human
arankal
et
al
illumin
analyz
viral
event
cytokin
storm
critic
illhospit
patient
investig
show
die
differ
influenza
viral
load
recov
howev
patient
recov
left
hospit
significantli
lower
cytokin
storm
profil
popul
succumb
infect
colleagu
hugh
rosen
reason
calm
host
aggress
exagger
cytokin
storm
respons
might
provid
opportun
shift
balanc
sever
morbid
mortal
surviv
laboratori
start
jointli
year
ago
test
hypothesi
marsolai
et
al
select
molecul
sphingosin
sought
determin
harm
immunolog
process
accompani
influenza
infect
could
modul
receptor
lung
select
agonist
document
histori
modul
lymphoid
traffick
induc
sequestr
lymphocyt
secondari
lymphoid
region
mean
agonist
limit
migrat
effector
lymphocyt
area
cell
mediat
immunolog
injuri
rosen
et
al
see
chap
rosen
cyster
volum
signal
lipid
present
concentr
nm
plasma
approxim
nm
lymph
physiolog
level
tight
homeostat
control
signal
specif
receptor
five
receptor
five
specif
receptor
coupl
differ
g
protein
purpos
regul
varieti
downstream
pathway
specif
mani
cell
tissu
organ
rosen
et
al
infiltr
lymphoid
cell
pulmonari
tissu
accompani
influenza
viru
infect
identifi
quantit
cell
specif
recogn
influenza
separ
virusspecif
effector
cell
major
bystand
cell
nonspecif
drawn
lung
chemotox
attract
releas
viral
induc
damag
infect
pulmonari
epitheli
cell
took
advantag
wealth
reagent
other
creat
lymphocyt
choriomening
viru
lcmv
colleagu
yoshi
kawaoka
cowork
use
revers
genet
marsolai
et
al
place
mhc
dbrestrict
immunodomin
lcmv
cell
epitop
glycoprotein
gp
mhc
iab
restrict
immunodomin
cell
epitop
gp
neuroaminidas
stalk
wsn
influenza
viru
technolog
gener
recombin
wsn
flulcmv
viru
replic
vivo
display
pulmonari
geographi
wildtyp
wt
wsn
viru
experiment
plan
util
gfp
rfplabel
clone
lcmv
recognit
lymphocyt
obtain
cell
receptor
mice
fluoroprobelabel
lymphocyt
recogn
lcmv
gp
fluoroprobelabel
lymphocyt
recogn
gp
gfprfplabel
virusspecif
lymphocyt
adopt
transfer
mice
resid
secondari
lymphoid
tissu
rest
lymphocyt
two
day
later
recombin
wsn
flulcmv
administ
intratrach
viru
replic
pulmonari
epitheli
cell
fig
follow
infiltr
virusspecif
cell
red
virusspecif
cell
green
fig
day
marsolai
et
al
kinet
studi
infiltr
virusspecif
cell
show
arriv
day
peak
amount
day
signific
numer
decreas
day
postinfect
fig
five
receptor
ie
administr
permiss
agonist
aalr
signal
receptor
receptor
significantli
reduc
number
virusspecif
cell
enter
lung
fig
result
signific
protect
pulmonari
tissu
injuri
fig
relat
mortal
fig
compar
effect
vehicl
alon
use
control
isom
aal
abl
phosphoryl
signal
receptor
blunt
innat
cytokin
chemokin
respons
follow
aalr
treatment
evid
remark
day
postinfluenza
infect
fig
observ
initi
made
murin
wsn
viru
later
confirm
use
nonmurin
adopt
human
pathogen
influenza
virus
walsh
et
al
studi
influenza
virus
although
cytokinechemokin
express
significantli
blunt
agonist
aalr
aalrtreat
mice
termin
viru
infect
display
robust
virusspecif
ctl
respons
day
influenza
infect
measur
releas
assay
also
mount
vigor
specif
memori
cell
respons
upon
rechalleng
viru
day
infect
kinet
titer
neutral
antiinfluenza
antibodi
sera
immunoglobulin
subtyp
either
aalr
aal
vehicletr
mice
equival
togeth
result
document
valid
premis
permiss
agonist
aalr
signal
via
receptor
given
local
respiratori
tract
downmodul
number
virusspecif
cell
decreas
innat
cytokinechemokin
express
lung
parenchyma
reduc
suppli
innat
inflammatori
pmn
macrophag
marsolai
et
al
walsh
et
al
abort
cytokin
storm
success
outcom
protect
host
influenza
viru
infect
still
provid
antivir
respons
curtail
eventu
imped
influenza
infect
data
indic
mice
receiv
aalr
protect
p
five
die
infect
compar
dose
viru
kill
approxim
vehicl
aalstreat
mice
mice
die
walsh
et
al
interestingli
optim
dose
current
use
antivir
drug
tamiflu
administ
protect
significantli
less
effect
live
mice
treat
compar
surviv
aalr
therapi
alon
result
document
promin
role
cytokin
storm
caus
death
influenza
infect
import
benefit
agonist
therapi
victim
multipl
influenza
viru
strain
especi
resist
antineuraminidas
therapi
although
greater
benefit
obtain
block
cytokin
storm
agonist
tamiflu
vs
protect
administ
antivir
drug
agonist
combin
therapi
optim
yield
protect
rate
influenza
viru
challeng
mice
surviv
infect
walsh
et
al
five
receptor
coupl
differ
g
protein
requir
mani
downstream
signal
pathway
fig
rosen
et
al
chap
volum
biolog
function
variou
receptor
depend
celltissu
locat
receptor
express
activ
know
broadli
permiss
agonist
aalr
signal
via
receptor
significantli
downregul
cytokin
storm
protect
mice
effect
pathogen
human
influenza
infect
fig
panel
walsh
et
al
repeat
experi
shown
fig
panel
use
two
agonist
walsh
et
al
teijaro
et
al
result
display
fig
indic
either
two
specif
receptor
agonist
whose
signal
entir
restrict
receptor
effect
broadli
permiss
aalr
signal
agonist
administ
intratrach
mgkg
intratrach
mgkg
oral
mgkg
teijaro
et
al
receptor
agonist
molecul
provid
protect
lethal
intranas
challeng
human
fig
blunt
cytokin
storm
fig
receptor
agonist
significantli
inhibit
secret
cytokin
chemokin
associ
influenza
viru
infect
name
observ
sever
experi
indic
amount
cytokineschemokin
inhibit
degre
similar
aalr
treatment
select
agonist
also
significantli
blunt
accumul
innat
infiltr
inflammatori
cell
fig
panel
notabl
reduct
macrophagesmonocyt
mark
neutrophil
natur
killer
cell
correspondingli
quantiti
activ
marker
significantli
reduc
follow
agonist
therapi
pulmonari
tissu
also
reflect
benefici
outcom
sinc
histolog
studi
mice
given
remedi
manifest
mostli
open
alveolar
air
space
diminish
neglig
inflammatori
cell
infiltr
neither
edema
hemorrhag
lung
tissu
importantli
agonist
treatment
enhanc
viral
titer
influenza
infect
effect
termin
antiinfluenza
neutral
antibodi
antiinfluenza
viru
cell
gener
although
number
cell
reduc
compar
infect
mice
receiv
agonist
therapi
suffici
termin
infect
immun
memori
establish
follow
therapi
thu
sever
pulmonari
injuri
diseas
associ
influenza
infect
result
cytokin
storm
treatabl
prepar
compos
receptor
agonist
molecul
therebi
avoid
signal
receptor
pharmaceut
may
import
ifwhen
individu
signal
might
lead
unwant
harm
biolog
effect
identifi
signal
primari
pathway
initi
cytokin
storm
sought
identifi
cell
cell
lung
express
receptor
sinc
epitheli
cell
primari
cell
infect
influenza
virus
suspect
receptor
might
locat
cell
determin
pulmonari
cell
type
bear
receptor
took
advantag
receptor
knockin
mice
made
stuart
cahalan
rosen
laboratori
cahalan
et
al
see
cahalan
chap
volum
strain
mice
nativ
receptor
homolog
replac
function
fuse
egfptag
receptor
cahalan
et
al
util
mous
model
could
directli
detect
receptor
protein
express
pulmonari
cell
use
antibodi
specif
pulmonari
cell
marker
flow
cytometri
fig
panel
addit
substanti
came
biochem
analysi
purifi
pulmonari
cell
fig
panel
b
receptor
express
plenti
lung
lymphat
vascular
endotheli
cell
surprisingli
absent
pulmonari
epitheli
cell
epcam
fig
panel
teijaro
et
al
result
confirm
western
blot
pure
popul
pulmonari
endotheli
epitheli
cell
fig
panel
b
expect
previous
report
cell
cell
b
cell
also
express
receptor
fig
panel
contrast
pulmonari
leukocyt
includ
macrophagesmonocyt
dendrit
cell
iaie
neutrophil
nk
cell
fig
panel
immatur
lymphoid
cell
fail
express
signific
level
receptor
protein
receptor
express
similar
whether
cell
harvest
mice
uninfect
infect
influenza
viru
experi
infect
mice
indic
receptor
express
alter
influenza
viru
infect
importantli
agonist
treatment
infect
receptor
knockin
mice
lessen
express
receptor
indic
administr
specif
agonist
degrad
endotheli
receptor
result
signifi
function
agon
antagonist
effect
receptor
degrad
mechan
receptor
block
molecul
suppress
cytokin
storm
studi
pulmonari
endotheli
cell
process
greater
puriti
first
h
follow
influenza
viru
infect
treat
agonist
assess
rna
protein
level
show
agonist
effect
decreas
amount
cytokin
chemokin
made
vascular
well
lymphat
pulmonari
endotheli
cell
fig
b
lymphocyt
well
pulmonari
endotheli
cell
cell
within
lung
express
measur
amount
protein
fig
panel
therefor
determin
whether
lymphocyt
express
receptor
involv
agonist
inhibit
cytokin
storm
mere
bystand
cell
accompani
innat
immun
respons
influenza
viru
infect
sinc
mice
defici
lymphocyt
reason
mice
infect
influenza
viru
gener
cytokin
storm
could
block
agonist
lymphocyt
rule
initi
cytokin
storm
experi
document
cytokin
storm
occur
mice
infect
influenza
viru
importantli
treatment
infect
mice
agonist
significantli
reduc
cytokin
chemokin
bronchial
lavag
fluid
well
minim
infiltr
innat
cell
macrophagesmonocyt
nk
cell
recent
john
teijaro
util
cell
sort
biochem
approach
found
receptor
plasmacytoid
dendrit
cell
pdc
whose
express
undetect
gfp
transgen
mous
model
observ
fig
b
detail
teijaro
et
al
amount
type
interferon
almost
exclus
speci
elev
earli
acut
influenza
viru
infect
releas
action
type
interferon
crucial
product
proinflammatori
cytokineschemokin
sinc
blockag
type
interferon
respons
use
monoclon
antibodi
receptor
significantli
reduc
quantiti
pulmonari
cytokineschemokin
associ
acut
influenza
infect
fig
treatment
receptor
agonist
inhibit
product
pulmonari
bronchial
lavag
fluid
earli
initi
influenza
viru
infect
proof
blunt
product
mechan
receptor
agonist
inhibit
cytokin
storm
deriv
use
receptor
knockout
mice
infect
viru
treat
receptor
agonist
studi
show
signific
reduct
cytokineschemokin
shown
fig
shown
bronchial
lavag
fluid
compar
result
similar
experiment
mice
intact
receptor
signal
abil
fig
interest
blockag
receptor
signal
retard
pulmonari
infiltr
inflammatori
monocyt
neutrophil
nk
receptor
agonist
therapi
fig
thu
infiltr
innat
inflammatori
cell
blunt
suffici
mice
receptor
knockout
mice
outcom
indic
regul
cell
recruit
lung
primarili
mediat
endotheli
cell
independ
type
interferon
signal
teijaro
et
al
cytokinechemokin
product
lung
also
mediat
pulmonari
endotheli
cell
receptor
agon
cell
inhibit
product
lead
significantli
diminish
inflammatori
cytokinechemokin
respons
observ
influenza
viru
infect
induc
robust
interferon
type
respons
despit
earli
induct
viral
protein
suppress
cellular
induct
respons
interferon
fernandezsesma
predomin
type
interferon
produc
earli
follow
influenza
viru
infect
alpha
beta
fig
howev
cellular
sourc
interferon
type
produc
amount
made
variou
cell
popul
clear
two
major
pulmonari
cell
popul
known
make
type
interferon
vivo
follow
respiratori
viral
infect
pdc
alveolar
macrophag
kumagai
et
al
judg
contribut
pdc
product
lung
util
novel
mous
model
recent
develop
scripp
bruce
beutler
term
feebl
feebl
mice
specif
genet
defect
prevent
pdc
produc
type
interferon
proinflammatori
cytokin
upon
activ
ligand
influenza
viru
stimul
blasiu
et
al
importantli
disrupt
number
vital
pdc
feebl
mous
defect
specif
restrict
pdc
display
fig
wild
type
feebl
mice
receiv
human
swine
influenza
without
agonist
treatment
total
produc
pdc
releas
significantli
inhibit
agonist
result
confirm
use
pdc
deplet
antibodi
clone
result
signific
deplet
pdc
lung
correspond
reduct
thu
pdc
essenti
major
produc
involv
amplif
cytokinechemokin
volum
follow
influenza
infect
deplet
studi
indic
remain
product
alveolar
macrophag
sinc
agonist
therapi
diminish
product
major
produc
pdc
import
learn
whether
pdc
express
receptor
surfac
know
alveolar
macrophag
main
albeit
minor
produc
express
receptor
fig
plasmacytoid
dendrit
cell
recent
found
express
receptor
teijaro
howev
use
egfp
receptor
knockin
mice
pdc
puriti
fail
show
cell
express
receptor
fig
thu
receptor
found
primarili
pulmonari
endotheli
cell
lesser
amount
pulmonari
pdc
receptor
agonist
act
directli
pulmonari
endotheli
pdc
like
indirectli
alveolar
macrophag
yet
unabl
detect
receptor
alveolar
macrophag
work
model
base
accumul
data
earliest
event
influenza
infect
provid
fig
although
sever
possibl
scenario
select
simplest
one
agonist
signal
factor
block
neg
signal
releas
pulmonari
pdc
migrat
innat
inflammatori
cell
blood
vessel
lung
model
base
presenc
receptor
pulmonari
endotheli
pdc
absenc
lung
epitheli
cell
find
alveolar
macrophag
produc
type
interferon
display
receptor
surfac
howev
pulmonari
endotheli
cell
pulmonari
pdc
express
receptor
surfac
cytokineschemokin
elicit
initi
cytokin
storm
reflect
factor
viral
nonvir
produc
influenza
virusinfect
lung
epitheli
cell
per
se
factor
like
activ
pulmonari
pdc
alveolar
macrophag
releas
chemotox
factor
liber
site
action
infiltr
cell
innat
immun
system
macrophagesmonocyt
nk
cell
leukocyt
drawn
inflammatori
milieu
releas
addit
cytokineschemokin
initi
respons
second
stage
occur
day
see
via
mechan
describ
public
marsolai
et
al
influenza
virusspecif
cell
activ
expand
numer
mediastin
lymph
node
pulmonari
tissu
cell
adopt
immun
system
produc
addit
inflammatori
molecul
lyse
influenza
virusinfect
epitheli
cell
therebi
augment
cytokin
storm
immunemedi
injuri
second
phase
tissu
injuri
primarili
influenza
cellmedi
signal
also
like
progress
via
receptor
preliminari
result
howev
addit
data
requir
ensur
observ
clear
treatment
permissiveaalr
agonist
signal
via
receptor
affect
adopt
immun
cellmedi
immunopatholog
downregul
mhc
costimulatori
molecul
dc
locat
mediastin
lymph
node
lung
parenchyma
therebi
blunt
arm
expans
migrat
virusspecif
cell
lung
marsolai
et
al
cytokin
pathway
blunt
agonist
signal
display
fig
symbol
cytokin
storm
play
essenti
role
pathogenesi
clinic
outcom
influenza
viru
infect
blockad
cytokin
storm
provid
greater
protect
antivir
therapi
like
neuraminidas
inhibitor
without
compromis
control
clearanc
virus
moreov
optim
therapi
achiev
combin
agonist
antineuraminidas
treatment
forego
observ
human
pathogen
influenza
viru
mous
adapt
influenza
viru
use
receptor
agonist
blunt
cytokin
storm
importantli
cytokin
storm
chemic
disarm
administ
one
five
receptor
molecular
mechan
event
involv
receptor
signal
pulmonari
endotheli
cell
pulmonari
pdc
viral
infect
epitheli
cell
alveolar
macrophag
pulmonari
endotheli
cell
major
gateway
combin
pulmonari
pdc
precipit
cytokin
storm
agon
suppress
recruit
cytokin
innat
adopt
immun
cell
blunt
innat
immun
cell
function
virusspecif
cell
activ
lessen
morbid
prevent
mortal
associ
experiment
model
influenza
viru
infect
mice
ferret
speci
suffici
antivir
respons
remain
termin
viru
infect
provid
immun
memori
upon
rechalleng
immun
cell
infiltr
cytokin
product
distinct
event
orchestr
endotheli
pdc
cell
proinflammatori
cytokin
respons
depend
type
interferon
signal
predomin
interferon
made
predomin
pulmonari
cell
make
type
interferon
pdc
alveolar
macrophag
make
rest
investig
interferon
cellular
sourc
signal
pathway
influenza
systemdissect
crosstalk
signal
pulmonari
endotheli
cell
infect
epitheli
cell
interferonproduc
pdc
identifi
molecul
involv
see
molecul
provid
potenti
therapeut
targetsdetermin
gener
acut
respiratori
infect
eg
hantaviru
respiratori
syncyti
viru
sar
pneumococc
pneumonia
cytokin
storm
play
promin
rolestudi
anim
model
subhuman
primat
reflect
influenza
human
result
studi
ferret
teijaro
et
al
mirror
protect
suppli
agonist
therapi
defend
influenza
viru
infect
murin
modeldefin
pathway
design
genet
screen
identifi
human
suscept
cytokin
stormdevelop
specif
receptor
agonist
antagonist
human
therapeut
focus
initi
molecul
